SCHEMBL1497178

SCHEMBL1497178

CC1(C)CCC(Br)=C(C=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19183030 0.83
SCHEMBL26023752 0.80 KDM4E (0.34)
SCHEMBL16168100 0.79
SCHEMBL18306655 0.77
SCHEMBL13331723 0.77
SCHEMBL26648422 0.76 FFAR3 (0.39)
SCHEMBL16076083 0.72
SCHEMBL1700803 0.71
SCHEMBL19203930 0.71
SCHEMBL22581347 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084607-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2011-12-27 US claimed
US-20100022773-A1 APOPTOSIS PROMOTERS ABBVIE INC. 2010-01-28 US claimed
US-12220419-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2025-02-11 US disclosed
EP-4397661-A1 COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2024-07-10 EP disclosed
US-20230295183-A1 HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR NEWAVE PHARMACEUTICAL INC. 2023-09-21 US disclosed
US-20230265065-A1 SELECTIVE PHOSPHATASE INHIBITORS BASED ON ILLUDALIC ACID THE WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY 2023-08-24 US disclosed
US-20230265065-A1 SELECTIVE PHOSPHATASE INHIBITORS BASED ON ILLUDALIC ACID THE WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY 2023-08-24 US disclosed
CN-116270660-A Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof 广州麓鹏制药有限公司 2023-06-23 CN disclosed
CN-116236583-A Bcl-2/Bcl-xl inhibitor-containing composition and preparation method and application thereof 广州麓鹏制药有限公司 2023-06-09 CN disclosed
EP-4110298-A1 HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-01-04 EP disclosed
CN-115484933-A Hot melt extrusion solid dispersions containing BCL2 inhibitors 广州麓鹏制药有限公司 2022-12-16 CN disclosed
US-8084607-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2011-12-27 US disclosed
US-8084607-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2011-12-27 US disclosed
US-20110312969-A1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110312969-A1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
WO-2011029842-A1 SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER NOVARTIS AG (CH) 2011-03-17 WO disclosed
EP-1953161-B1 New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2009-08-26 EP disclosed
WO-2008110691-A1 NOVEL TRICYCLIC DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2008-09-18 WO disclosed
US-20080188460-A1 Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2008-08-07 US disclosed
EP-1953161-A1 New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2008-08-06 EP disclosed